A study by Gilead shows 36 out of 53 patients (68%), who were hospitalized for severe Covid-19, showed clinical improvement on treatment with Remdesivir.
Mumbai| The Indian Council of Medical Research (ICMR) said that it’ll use Remdesivir, an experimental drug by Gilead sciences if the local manufacturers in India can produce the drug. The drug can be used to treat Covid-19 patients.
“Initial data based on an observational study shows that the drug is effective. We will wait for the results from the WHO solidarity trial and also see if some other companies can work on this to proceed further,” Raman Gangakhedkar, the head scientist at ICMR said.
Remdesivir was used in the treatment of Ebola patients. A study by Gilead shows 36 out of 53 patients (68%), who were hospitalized for severe Covid-19, showed clinical improvement on treatment with Remdesivir.
“Remdesivir is an investigational treatment and has not been approved for use anywhere in the world. “In the broader efforts to determine whether it is a safe and effective treatment, we have some way to go,” Daniel O’Day, the CEO of Gilead, wrote on 10th April.
O’day informed that multiple trials are underway across the world to analyze how the drug works in different contexts.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
